|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Exp. Med.,
Volume 189, Number 7, April 5, 1999 1033-1042
By


From the * Department of Immunology, Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model for multiple
sclerosis (MS). EAE is typically initiated by CD4+ T helper cell type 1 (Th1) autoreactivity directed against a single priming immunodominant myelin peptide determinant. Recent studies
have shown that clinical progression of EAE involves the accumulation of neo-autoreactivity,
commonly referred to as epitope spreading, directed against peptide determinants not involved in the priming process. This study directly addresses the relative roles of primary autoreactivity
and secondary epitope spreading in the progression of both EAE and MS. To this end we serially evaluated the development of several epitope-spreading cascades in SWXJ mice primed with
distinctly different encephalitogenic determinants of myelin proteolipid protein. In a series of
analogous experiments, we examined the development of epitope spreading in patients with
isolated monosymptomatic demyelinating syndrome as their disease progressed to clinically
definite MS. Our results indicate that in both EAE and MS, primary proliferative autoreactivity associated with onset of clinical disease invariably regresses with time and is often undetectable
during periods of disease progression. In contrast, the emergence of sustained secondary autoreactivity to spreading determinants is consistently associated with disease progression in both
EAE and MS. Our results indicate that chronic progression of EAE and MS involves a shifting
of autoreactivity from primary initiating self-determinants to defined cascades of secondary determinants that sustain the self-recognition process during disease progression.
Mellen Center for Multiple
Sclerosis Research and Treatment, The Cleveland Clinic Foundation, Cleveland, Ohio 44195
This article has been cited by other articles:
| TABLE OF CONTENTS |
|